Haiping Jiang1, Xinyan Shi2, Xiaoyun Yu1, Xinjia He1, Yongheng An1, Haijun Lu3. 1. Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China. 2. North Administration Office, Affiliated Hospital of Qingdao University, Qingdao, 26600, China. 3. Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China. LavoneHeroapusb@yahoo.com.
Abstract
PURPOSE: In this study, we have successfully prepared the hyaluronic acid (HA)-conjugated mesoporous silica nanoparticles loaded with 5-fluorouracil (5-FU) to increase the anticancer efficacy in colon cancers. METHODS: The particles were nanosized and perfectly spherical. In vitro release kinetics clearly showed the enzyme-sensitive release of 5-FU from HA-conjugated 5-FU loaded mesoporous silica nanoparticles (HA/FMSN). RESULTS: The presence of HA on the surface of nanoparticles targeted the CD44 receptors overexpressed in the colon cancer cells In vitro cell viability and apoptosis assay clearly showed the superior anticancer effect of HA/FMSN in HT29 colon cancer cells. HA/FMSN exhibited a remarkably higher 43% of cells in early apoptosis phase and 55% of cells in late apoptosis phase indicating the superior anticancer effect of HA/FMSN. HA/FMSN exhibited a significant reduction in the tumor burden compared to that of any group. HA/FMSN was 3-fold more effective than free drug and 2-fold more effective than -FU loaded mesoporous silica nanoparticles (FMSN). CONCLUSIONS: Overall, results suggest that the novel delivery strategy could hold enormous potential in colon cancer targeting.
PURPOSE: In this study, we have successfully prepared the hyaluronic acid (HA)-conjugated mesoporous silica nanoparticles loaded with 5-fluorouracil (5-FU) to increase the anticancer efficacy in colon cancers. METHODS: The particles were nanosized and perfectly spherical. In vitro release kinetics clearly showed the enzyme-sensitive release of 5-FU from HA-conjugated 5-FU loaded mesoporous silica nanoparticles (HA/FMSN). RESULTS: The presence of HA on the surface of nanoparticles targeted the CD44 receptors overexpressed in the colon cancer cells In vitro cell viability and apoptosis assay clearly showed the superior anticancer effect of HA/FMSN in HT29 colon cancer cells. HA/FMSN exhibited a remarkably higher 43% of cells in early apoptosis phase and 55% of cells in late apoptosis phase indicating the superior anticancer effect of HA/FMSN. HA/FMSN exhibited a significant reduction in the tumor burden compared to that of any group. HA/FMSN was 3-fold more effective than free drug and 2-fold more effective than -FU loaded mesoporous silica nanoparticles (FMSN). CONCLUSIONS: Overall, results suggest that the novel delivery strategy could hold enormous potential in colon cancer targeting.
Authors: Cristina Giménez; Cristina de la Torre; Mónica Gorbe; Elena Aznar; Félix Sancenón; Jose R Murguía; Ramón Martínez-Máñez; M Dolores Marcos; Pedro Amorós Journal: Langmuir Date: 2015-03-16 Impact factor: 3.882
Authors: Ki Young Choi; Hong Yeol Yoon; Jong-Ho Kim; Sang Mun Bae; Rang-Woon Park; Young Mo Kang; In-San Kim; Ick Chan Kwon; Kuiwon Choi; Seo Young Jeong; Kwangmeyung Kim; Jae Hyung Park Journal: ACS Nano Date: 2011-10-11 Impact factor: 15.881
Authors: Stephen J Clarke; Christos S Karapetis; Peter Gibbs; Nick Pavlakis; Jayesh Desai; Michael Michael; Niall C Tebbutt; Tim J Price; Josep Tabernero Journal: Crit Rev Oncol Hematol Date: 2012-07-02 Impact factor: 6.312
Authors: Raúl Ortiz; José Prados; Consolación Melguizo; José L Arias; M Adolfina Ruiz; Pablo J Alvarez; Octavio Caba; Raquel Luque; Ana Segura; Antonia Aránega Journal: Int J Nanomedicine Date: 2012-01-09
Authors: Abdelkader E Ashour; Mohammad Badran; Ashok Kumar; Tajamul Hussain; Ibrahim A Alsarra; Alaa Eldeen B Yassin Journal: Int J Nanomedicine Date: 2019-11-28
Authors: Ilaria Ottonelli; Riccardo Caraffi; Giovanni Tosi; Maria Angela Vandelli; Jason Thomas Duskey; Barbara Ruozi Journal: Int J Mol Sci Date: 2022-02-17 Impact factor: 5.923